Revolutionizing personalized dermatology with Advanced AI, Digital Monitoring and OMIC Technologies

Summary

Profile Type: Technology offer
POD Reference: TODE20231207018
Term of Validity: 11 December 2023 - 10 December 2024
Company's Country: Germany
Type of partnership: Research and development cooperation agreementInvestment agreementCommercial agreement with technical assistance
Targeted Countries: All countries

Contact the EEN partner nearest to you for more information.

Find my local partner

General information

Short Summary: German SME and innovative leader in dermatology, specializes in personalized treatment of Chronic Inflammatory Skin Conditions (CISCs) using a unique blend of AI, environmental digital monitoring, and OMIC technologies. Their approach focuses on understanding each patient's unique illness pathways to tailor best therapeutic solutions. They offer comprehensive services to patients, dermatologists, and pharmaceutical industry, ensuring personalized care and groundbreaking treatment methodologies.
Full Description: The German SME stands at the forefront of personalized medicine in dermatology, specializing in a wide array of Chronic Inflammatory Skin Conditions (CISCs) such as Atopic Dermatitis, Psoriasis, Contact Dermatitis, Urticaria, Vitiligo, and various forms of Skin Cancer, including Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma.
Their approach uniquely combines state-of-the-art OMIC technologies with a proprietary AI algorithm that is singular in its ability to unravel the complex, multidimensional aspects entangled in High-Throughput Processing (HTP) from OMICs data. This advanced AI technology allows them to discern disease patterns and molecular pathophysiology that are beyond the reach of traditional software or statistical analyses. By doing so, they do not only go beyond symptomatic treatment but also aim for a lasting transformation in their patients' lives through personalized and precise therapeutic strategies.
Their services are comprehensive, offering detailed consultations and diagnostic packages, including in-depth analyses of mRNAs, proteins, and immune cells. This approach ensures the most effective therapeutic solutions tailored to each individual’s unique condition. Dermatologists benefit from their AI-powered tools and extensive data repository, enhancing patient care and facilitating cutting-edge research. Moreover, their collaboration with pharmaceutical partners in disease discovery and clinical studies utilizes their advanced OMIC platforms and AI pipeline, further advancing dermatology. The SME is driven by a team of experts committed to changing the narrative in dermatological care. By focusing on these specific diseases and employing their unique AI technology, they lead the way in the new era of personalized dermatology, offering hope and revolutionary treatments to patients across the globe.

The SME is keen to partner with companies, research organizations or hospitals that have a strong interest in personalized dermatology and therapy optimization as they see great potential in applying their OMIC platforms and AI technology for disease discovery and clinical studies in partnership with other entities.

Their cooperation proposal involves using their advanced AI software to identify unique patient subtypes based on up to 300,000 data points per patient, offering insights into treatment efficacy. This approach, similar to multidimensional biomarkers, enables patient categorization based on their likely response to specific treatments.
In terms of partnership roles and expertise, the SME is looking for hospitals with:
1. Extensive tissue databases for comprehensive skin disease screening.
2. Experience or interest in research and development in dermatology and personalized medicine.
The objective is to unearth molecular patterns that may allow for the repurposing of existing pharmaceutical drugs for specific patient subpopulations or endotypes. Achieving this will allow collaborating with pharmaceutical companies, offering services to conduct studies that verify the potential of repurposing their drugs for the identified patient groups or endotypes.

As for EU Project involvement, the SME is open to both joining as a partner in an existing consortium or leading a project. Their focus would be on R&D cooperation agreements within the realm of dermatology and personalized medicine. They are particularly interested in calls that align with their expertise in AI-driven data analysis and patient-specific treatment strategies. This innovative approach promises to transform personalized medicine, opening new paths for endotype-specific therapies.

The SME is also open to investment agreements for the development of specific applications of their AI technology.
Advantages and Innovations: The company’s service, a pioneering innovation in dermatology, leverages advanced OMIC technologies and AI to redefine the treatment of Chronic Inflammatory Skin Conditions (CISCs). The AI-driven approach deciphers complex OMICs data, revealing disease patterns and enabling tailored treatment strategies beyond the capabilities of current diagnostic methods.

Unlike traditional symptom-based diagnostics, the company’s methodology and service offers precise identification of disease mechanisms, leading to more accurate diagnoses. Quantitatively, it reduces misdiagnosis rates, which are typically as high as 44% in CISCs, and minimizes ineffective treatment trials. By employing targeted therapies, the company’s solution lowers the usage of broad-spectrum immunosuppressants, reducing associated side effects by up to 60% and cutting down on long-term healthcare costs. This personalized approach translates to a 50% improvement in treatment outcomes and a significant reduction in the time to reach effective therapy, from months to just a few weeks.

Comparatively, prevailing diagnostic methods in dermatology heavily rely on symptomatic analysis, often leading to generalized treatments that don't consider individual patient differences. In contrast, the company’s comprehensive analysis incorporates molecular, environmental, and lifestyle factors, offering a holistic view of each patient’s condition. This results in a superior therapeutic strategy with fewer side effects and a higher success rate. Economically, the offered methodology stands out by reducing the financial burden on healthcare systems. By avoiding trial-and-error treatment approaches and reducing the need for prolonged therapy, it significantly lowers overall treatment costs. Additionally, the reduction in misdiagnoses and ineffective treatments leads to better resource allocation and increased patient satisfaction, marking the company’s approach as a leading solution in personalized dermatology care.
Stage of Development: Available for demonstration
Sustainable Development Goals: Goal 3: Good Health and Well-being

Partner Sought

Expected Role of a Partner: Type of partner sought:
Industrial, academic and hospitals

Specific area of activity of the partner: Drug development, dermatology applications

Tasks to be performed by the partner sought/Expected role of the partner:
- Partners should be interested in applying the OMIC platforms and AI technology for disease discovery and clinical studies.
- Hospitals should provide extensive tissue databases for comprehensive skin disease screening and
be experienced or interested in research and development in dermatology and personalized
medicine.
- Investors should be interested in the development of specific applications of the company’s AI
technology
Type and Size of Partner: OtherR&D InstitutionUniversitySME 11-49Big companySME <=10SME 50 - 249
Type of partnership: Research and development cooperation agreementInvestment agreementCommercial agreement with technical assistance

Call details

Coordinator required: Yes

Dissemination

Technology keywords: 01003003 - Artificial Intelligence (AI)01003006 - Computer Software06001005 - Diagnostics, Diagnosis01004001 - Applications for Health
Market keywords: 02007012 - Medical/health software05001005 - Molecular diagnosis02007016 - Artificial intelligence related software05007006 - Computer-aided diagnosis and therapy05005001 - Allergy research
Sector Groups Involved: DigitalHealth
Targeted countries: All countries